PL3576771T3 - Kompozycje i sposoby długotrwałego uwalniania antagonistów gonadoliberyny (GnRH) - Google Patents

Kompozycje i sposoby długotrwałego uwalniania antagonistów gonadoliberyny (GnRH)

Info

Publication number
PL3576771T3
PL3576771T3 PL18747581.9T PL18747581T PL3576771T3 PL 3576771 T3 PL3576771 T3 PL 3576771T3 PL 18747581 T PL18747581 T PL 18747581T PL 3576771 T3 PL3576771 T3 PL 3576771T3
Authority
PL
Poland
Prior art keywords
ganadotropin
gnrh
antagonists
compositions
methods
Prior art date
Application number
PL18747581.9T
Other languages
English (en)
Inventor
Kacker RAVI
Steiner MITCHELL S.
Original Assignee
Veru Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veru Inc. filed Critical Veru Inc.
Publication of PL3576771T3 publication Critical patent/PL3576771T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18747581.9T 2017-01-31 2018-01-31 Kompozycje i sposoby długotrwałego uwalniania antagonistów gonadoliberyny (GnRH) PL3576771T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452788P 2017-01-31 2017-01-31
PCT/US2018/016241 WO2018144603A1 (en) 2017-01-31 2018-01-31 COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS

Publications (1)

Publication Number Publication Date
PL3576771T3 true PL3576771T3 (pl) 2022-08-16

Family

ID=62976965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18747581.9T PL3576771T3 (pl) 2017-01-31 2018-01-31 Kompozycje i sposoby długotrwałego uwalniania antagonistów gonadoliberyny (GnRH)

Country Status (19)

Country Link
US (2) US20180214507A1 (pl)
EP (2) EP4011386A1 (pl)
JP (1) JP7074963B2 (pl)
KR (1) KR20190110567A (pl)
CN (1) CN110234336A (pl)
AU (1) AU2018217064A1 (pl)
CA (1) CA3052157A1 (pl)
CY (1) CY1125582T1 (pl)
DK (1) DK3576771T3 (pl)
ES (1) ES2914314T3 (pl)
HR (1) HRP20220438T1 (pl)
HU (1) HUE058207T2 (pl)
IL (1) IL268376A (pl)
LT (1) LT3576771T (pl)
MX (2) MX391306B (pl)
PL (1) PL3576771T3 (pl)
PT (1) PT3576771T (pl)
UA (1) UA127018C2 (pl)
WO (1) WO2018144603A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7069155B2 (ja) 2017-06-29 2022-05-17 株式会社ソニー・インタラクティブエンタテインメント ロボットの制御装置、制御方法および制御プログラム
CN119236191A (zh) 2018-05-24 2025-01-03 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
MX2020012458A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3860573A1 (en) * 2018-10-02 2021-08-11 InnoCore Technologies Holding B.V. Extended release formulations of human chorionic gonadotropin (hcg)
CN110681323B (zh) * 2019-08-26 2021-12-21 上海摩漾生物科技有限公司 具有微拓扑结构的高尔夫球型可降解微球及其制备方法
WO2021237039A1 (en) * 2020-05-21 2021-11-25 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
EP4454636A4 (en) * 2021-12-24 2026-01-07 Sichuan Kelun Pharm Res Inst Co Ltd CONTINUOUS ADMINISTRATION PREPARATION THAT CAN BE STABLELY RELEASED AND ASSOCIATED PREPARATION PROCESS
US20260000612A1 (en) * 2022-06-23 2026-01-01 G2Gbio, Inc. Sustained-release microparticles containing drug and pamoic acid
WO2024131788A1 (zh) * 2022-12-23 2024-06-27 长春金赛药业有限责任公司 一种GnRH拮抗剂可注射组合物及其制备方法和应用
AU2024216901A1 (en) * 2023-02-10 2025-08-14 Tolmar International Limited Degarelix organic solvent formulations
EP4661840A2 (en) * 2023-02-10 2025-12-17 Tolmar International Limited Degarelix polymeric formulations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
CA2187353C (en) * 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US6805879B2 (en) 2000-06-23 2004-10-19 Biopharm Solutions Inc. Stable polymer aqueous/aqueous emulsion system and uses thereof
AU2001295359A1 (en) 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
KR100435921B1 (ko) 2000-12-29 2004-06-12 주식회사 태평양 동수역학적 이중 안정화에 의한 안정한 수-유-수 다중에멀젼 시스템 및 이의 제조방법
SI21222A (sl) 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
EP1382628A1 (en) * 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
KR100633280B1 (ko) 2002-09-27 2006-10-16 젠타리스 게엠베하 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US20060003008A1 (en) * 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US20080254086A1 (en) * 2004-12-23 2008-10-16 Brown James E Controlled Release Compositions
DK1939204T6 (da) 2005-10-19 2022-09-05 Kissei Pharmaceutical Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
ES2569556T3 (es) * 2008-06-03 2016-05-11 Indivior Uk Limited Complejo de inclusión de hidrogel deshidratado de un agente bioactivo con sistema fluido de administración de medicamento
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
TR200907227A2 (tr) 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
US9364442B2 (en) 2010-07-09 2016-06-14 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
CN102145160A (zh) * 2011-03-07 2011-08-10 深圳市健元医药科技有限公司 一种lhrh拮抗剂注射用的缓释植入制剂
EP2726504A1 (en) 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
WO2013015685A1 (en) 2011-07-22 2013-01-31 Innocore Technologies B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
JP2017508776A (ja) 2014-03-27 2017-03-30 ノバルティス アーゲー 医薬品有効成分吸入用の噴霧乾燥した水中油中固体分散体
US20170290846A1 (en) * 2014-09-30 2017-10-12 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
KR20190110567A (ko) 2019-09-30
CN110234336A (zh) 2019-09-13
CY1125582T1 (el) 2025-05-09
ES2914314T3 (es) 2022-06-09
EP4011386A1 (en) 2022-06-15
UA127018C2 (uk) 2023-03-15
JP7074963B2 (ja) 2022-05-25
EP3576771B1 (en) 2022-03-09
RU2019123951A3 (pl) 2021-08-02
AU2018217064A1 (en) 2019-08-08
JP2020506232A (ja) 2020-02-27
HUE058207T2 (hu) 2022-07-28
WO2018144603A1 (en) 2018-08-09
RU2019123951A (ru) 2021-02-01
MX2019009126A (es) 2020-01-20
EP3576771A1 (en) 2019-12-11
MX391306B (es) 2025-03-21
CA3052157A1 (en) 2018-08-09
PT3576771T (pt) 2022-05-30
LT3576771T (lt) 2022-04-11
EP3576771A4 (en) 2020-11-04
US20180214507A1 (en) 2018-08-02
HRP20220438T1 (hr) 2022-06-10
IL268376A (en) 2019-09-26
DK3576771T3 (da) 2022-05-30
MX2022003967A (es) 2022-04-25
US20180250354A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
IL268376A (en) Compositions for long-term release of gonadotropin-releasing hormone (GHRH) inhibitors and methods of their use
SG11202100214SA (en) Antagonists of t2r54 and compositions and uses thereof
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL261176B2 (en) Preparations for the controlled release of active ingredients and methods for their preparation
IL259634A (en) An improved apj apelin receptor agonist and uses thereof
IL259660B (en) Apelin receptor agonists and methods of use
LT3386484T (lt) Gydomųjų medžiagų sudėtis ir pristatymo metodai
PT3298043T (pt) Composições de polipéptido sirp e métodos de utilização
ZA201906169B (en) Synthekine compositions and methods of use
GB2542309B (en) Systems and methods for analyzing the characteristics and compositions of cement additives
SG10202004071UA (en) Cryoprecipitate compositions and methods of preparation thereof
SI3288379T1 (sl) Peptidne sestave in načini uporabe
IL281808A (en) Methods and preparations for the selection of functional aptamers
IL274524A (en) Preparations and methods for aquaculture
IL268072A (en) Methods and systems for improving the stability of electronic inhaler pre-vapor formulations
IL275739A (en) Preparations for cryopreservation and methods of their use
SG11202004506WA (en) METHODS FOR SELECTIVE EXPANSION OF d3 ?d T-CELL POPULATIONS AND COMPOSITIONS THEREOF
HUE055891T2 (hu) A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
SG11202002351SA (en) Poloxamer compositions and methods of making and using same
EP3672618A4 (en) COMPOSITIONS AND METHODS OF ADMINISTRATION OF PHARMACOLOGICAL AGENTS
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물